Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

R. Patel, Manesh; W. Mahaffey, Kenneth; Garg, Jyotsna; Pan, Guohua; E. Singer, Daniel; Hacke, Werner; Breithardt, Günter; L. Halperin, Jonathan; J. Hankey, Graeme; P. Piccini, Jonathan; C. Becker, Richard; C. Nessel, Christopher; F. Paolini, John; D. Berkowitz, Scott; A.A. Fox, Keith; M. Califf, Robert

doi:10.1056/nejmoa1009638

Public

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Published in New England Journal of Medicine • Aug 10, 2011

Authors:

Manesh R. Patel

Kenneth W. Mahaffey

Jyotsna Garg

Abstract

BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin. METHODS: In a double-bli...

Subject

Rivaroxaban

Medicine

Warfarin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!